Aprea Therapeutics (APRE) vs Jaguar Health (JAGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aprea Therapeutics is the larger company by market cap ($3.2 million vs $3.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APRE | JAGX |
|---|---|---|
| Share price | $0.229 | $0.227 |
| Market cap | $3.25M | $3.03M |
| 1-day change | -53.56% | -30.58% |
| EPS (TTM) | $-0.57 | $-257.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $11.51M |
| Revenue growth (YoY) | — | -1.52% |
| Net income (latest FY) | $-12.60M | $-53.58M |
| Gross margin | — | 67.21% |
| Operating margin | — | -398.82% |
| Net margin | — | -465.42% |
| 52-week high | $1.49 | $981.75 |
| 52-week low | $0.2036 | $0.22 |
| Distance from 52-week high | -84.63% | -99.98% |
| Analyst consensus | none | — |
| Avg. price target upside | +1528.82% | — |
| Average volume | 388.67K | 2.40M |
| Shares outstanding | 14.19M | 13.35M |
| Employees | 8 | 47 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Jaguar Health
JAGX stock →Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health.
Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees
APRE vs JAGX FAQ
Which is bigger, Aprea Therapeutics or Jaguar Health?
Aprea Therapeutics (APRE) is larger, with a market capitalization of $3.25M compared with $3.03M for Jaguar Health (JAGX).
Are Aprea Therapeutics and Jaguar Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.